Cerevel: The Big Thing In CNS Disease If Market Wasn't Crowded
Cerevel is a CNS specialist drug developer formed as a result of a spinout of former Pfizer neuroscience assets. The current valuation isn't attractive.
United States United Kingdom Paul Mcdougall Cerevel Therapeutics Holdings Purpose Acquisition Company Arya Sciences Acquisition Corp
Source: seekingalpha.com